UTHR – United Therapeutics Corporation
UTHR — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
5.1
Margin Of Safety %
-1
Put/Call OI Ratio
0.66
EPS Next Q Diff
-0.22
EPS Last/This Y
-3.21
EPS This/Next Y
4.59
Price
538.83
Target Price
664.33
Analyst Recom
1.5
Performance Q
-5.33
Upside
14.2%
Beta
0.56
Ticker: UTHR
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | UTHR | 535.41 | 1.52 | 2.69 | 17486 |
| 2026-07-14 | UTHR | 526.64 | 1.53 | 0.88 | 17628 |
| 2026-07-15 | UTHR | 531.97 | 1.53 | 6.06 | 17650 |
| 2026-07-16 | UTHR | 528.68 | 1.53 | 7.35 | 17667 |
| 2026-07-17 | UTHR | 535.67 | 1.51 | 1.32 | 17840 |
| 2026-07-20 | UTHR | 528.83 | 1.70 | 0.15 | 17279 |
| 2026-07-21 | UTHR | 535.48 | 1.69 | 2.13 | 17380 |
| 2026-07-22 | UTHR | 527.07 | 1.69 | 17.77 | 17527 |
| 2026-07-23 | UTHR | 529.63 | 1.80 | 8.67 | 18297 |
| 2026-07-24 | UTHR | 528.33 | 1.81 | 1.42 | 18398 |
| 2026-07-27 | UTHR | 527.77 | 1.81 | 6.22 | 18436 |
| 2026-07-28 | UTHR | 523.42 | 1.82 | 1.14 | 18475 |
| 2026-07-29 | UTHR | 524.77 | 1.82 | 274.86 | 18485 |
| 2026-07-30 | UTHR | 525.74 | 1.09 | 1.17 | 13716 |
| 2026-07-31 | UTHR | 517.46 | 1.09 | 0.26 | 13987 |
| 2026-08-03 | UTHR | 516.27 | 1.09 | 0.21 | 14003 |
| 2026-08-04 | UTHR | 518.59 | 1.09 | 1.54 | 14127 |
| 2026-08-05 | UTHR | 519.38 | 1.09 | 4.96 | 14739 |
| 2026-08-06 | UTHR | 532.79 | 1.12 | 0.53 | 15211 |
| 2026-08-07 | UTHR | 538.83 | 0.66 | 0.28 | 44721 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | UTHR | 535.41 | 9.9 | - | 27.28 |
| 2026-07-14 | UTHR | 526.27 | 9.9 | - | 26.85 |
| 2026-07-15 | UTHR | 531.78 | 9.9 | - | 26.85 |
| 2026-07-16 | UTHR | 528.68 | 9.9 | - | 26.85 |
| 2026-07-17 | UTHR | 535.39 | 9.9 | - | 26.85 |
| 2026-07-20 | UTHR | 529.59 | 9.9 | - | 26.85 |
| 2026-07-21 | UTHR | 535.77 | 9.9 | - | 26.85 |
| 2026-07-22 | UTHR | 527.02 | 9.9 | - | 26.85 |
| 2026-07-23 | UTHR | 529.41 | 9.9 | - | 26.85 |
| 2026-07-24 | UTHR | 528.29 | 9.9 | - | 26.85 |
| 2026-07-27 | UTHR | 527.70 | 9.8 | - | 26.91 |
| 2026-07-28 | UTHR | 523.42 | 9.6 | - | 26.92 |
| 2026-07-29 | UTHR | 524.66 | 9.6 | - | 26.92 |
| 2026-07-30 | UTHR | 526.07 | 9.6 | - | 26.92 |
| 2026-07-31 | UTHR | 517.46 | 9.6 | - | 26.92 |
| 2026-08-03 | UTHR | 516.42 | 9.6 | - | 26.92 |
| 2026-08-04 | UTHR | 516.42 | 9.6 | - | 26.92 |
| 2026-08-05 | UTHR | 518.70 | 9.6 | - | 26.92 |
| 2026-08-06 | UTHR | 532.67 | 9.6 | - | 26.92 |
| 2026-08-07 | UTHR | 538.83 | 0.0 | - | 26.92 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | UTHR | -48.41 | 0.10 | 5.17 |
| 2026-07-14 | UTHR | -47.96 | 0.10 | 5.17 |
| 2026-07-15 | UTHR | -48.13 | 0.10 | 5.17 |
| 2026-07-16 | UTHR | -48.37 | 0.10 | 5.17 |
| 2026-07-17 | UTHR | -48.69 | 0.10 | 5.17 |
| 2026-07-20 | UTHR | -48.86 | -0.20 | 5.17 |
| 2026-07-21 | UTHR | -49.03 | -0.20 | 5.17 |
| 2026-07-22 | UTHR | -49.13 | -0.20 | 5.17 |
| 2026-07-23 | UTHR | -49.30 | -0.20 | 5.17 |
| 2026-07-24 | UTHR | -49.46 | -0.20 | 5.17 |
| 2026-07-27 | UTHR | -49.79 | -0.33 | 5.10 |
| 2026-07-28 | UTHR | -49.95 | -0.33 | 5.10 |
| 2026-07-29 | UTHR | -49.34 | -0.33 | 5.10 |
| 2026-07-30 | UTHR | -49.51 | -0.33 | 5.10 |
| 2026-07-31 | UTHR | -49.43 | -0.33 | 5.10 |
| 2026-08-03 | UTHR | -49.60 | -0.56 | 5.10 |
| 2026-08-04 | UTHR | -49.37 | -0.56 | 5.10 |
| 2026-08-05 | UTHR | -49.56 | -0.56 | 5.10 |
| 2026-08-06 | UTHR | -49.86 | -0.56 | 5.10 |
| 2026-08-07 | UTHR | -49.86 | -0.56 | 5.10 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
7.27
Avg. EPS Est. Current Quarter
7
Avg. EPS Est. Next Quarter
7.05
Insider Transactions
-49.86
Institutional Transactions
-0.56
Beta
0.56
Average Sales Estimate Current Quarter
818
Average Sales Estimate Next Quarter
832
Fair Value
534.82
Quality Score
100
Growth Score
93
Sentiment Score
94
Actual DrawDown %
11.6
Max Drawdown 5-Year %
-33
Target Price
664.33
P/E
19.27
Forward P/E
18.59
PEG
2.41
P/S
7.33
P/B
3.59
P/Free Cash Flow
21.21
EPS
27.96
Average EPS Est. Cur. Y
26.92
EPS Next Y. (Est.)
31.51
Target Price Estimates Raised
1
Target Price Estimates Lowered
1
Profit Margin
41.56
Relative Volume
1.94
Return on Equity vs Sector %
-6.8
Return on Equity vs Industry %
13.7
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
-0.39
EBIT Estimation
◆
UTHR
Healthcare
$538.84
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
55
Range 1M
60%
Sup Dist
3.7%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-6.1%
EPS NY
10.8%
52W%
76.3%
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+18.8% upside
Upside
+18.8%
Quality
100
MoS
-1%
UTHR — P/E HistoricalBiotechnology
United Therapeutics CorporationSector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1400
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
UTHR
Latest News
—
Caricamento notizie per UTHR…
stock quote shares UTHR – United Therapeutics Corporation Stock Price stock today
news today UTHR – United Therapeutics Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch UTHR – United Therapeutics Corporation yahoo finance google finance
stock history UTHR – United Therapeutics Corporation invest stock market
stock prices UTHR premarket after hours
ticker UTHR fair value insiders trading